The substantial spending by a single large company indicates a significant market need for managing such costs, the platform could be built relatively quickly by integrating with existing HR and pharmacy benefit systems, there appears to be a gap in specialized tools for managing high-cost drug benefits, and the model is easily adaptable to different countries and healthcare systems.